A phase II study of isolated lung perfusion with melphalan followed by pulmonary metastasectomy in patients with resectable pulmonary metastases of colorectal carcinoma, soft tissue sarcoma and osteosarcoma

未提供0 个研究点目标入组 100 人开始时间: 2013年11月27日最近更新: 2014年2月3日

试验速览

暂无简介。

•Age of 18 years and older.
•Patients with pulmonary metastases from colorectal carcinoma, sarcomas of soft tissue and osteosarcomas
•Patients with pulmonary metastases from colorectal carcinoma, sarcomas of soft tissue and osteosarcomas
•?Cytologic/histologic proof or high clinical probability of pulmonary metastases of colorectal carcinoma, soft tissue sarcoma or osteosarcoma
•?No other systemic metastases present than pulmonary metastases
•?Primary site has been radically treated without signs of recurrence
•?Patient is a candidate for pulmonary metastasectomy with no more than 10 pulmonary metastases documented on CT scan of the thorax. Metastases must be located primarily in the periphery of the lungs.
•?No standard treatment options available, except pulmonary metastasectomy
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 2
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 1

•Pregnancy/lactation
•?Uncontrollable infectious disease
•?Liver/renal insufficiency; serum creatinine more than 130 µmol/l and urine creatinine clearance less than 60 ml/min, ALAT and ASAT more than 3 times normal.
•?Severe comorbidity
•?Previous thoracotomy or pleuropulmonary diseases resulting in obliteration of the pleural space

发起方

未提供